Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Egyptian International Pharmaceutical Investments Debt-to-EBITDA Related Terms
Egyptian International Pharmaceutical Investments Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Debt-to-EBITDA Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Debt-to-EBITDA of 2.82 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Egyptian International Pharmaceutical Investments. This is near median its historical median of 2.84. Over the past decade, Egyptian International Pharmaceutical Investments' Debt-to-EBITDA has ranged from 1.98 to 4.08. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #519 out of 675 companies in the Drug Manufacturers industry, placing it in the top 76.9%.
Is Egyptian International Pharmaceutical Investments' Debt-to-EBITDA too high?
Egyptian International Pharmaceutical Investments' current Debt-to-EBITDA of 2.82 is near median its 10-year median of 2.84. Over the past 10 years, this metric has ranged from a low of 1.98 to a high of 4.08. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Egyptian International Pharmaceutical Investments' value of 2.82 is 74.1% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #519 out of 675 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #519 out of 675 companies for Debt-to-EBITDA. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. Egyptian International Pharmaceutical Investments' value of 2.82 is 74.1% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Debt-to-EBITDA has ranged from 1.98 to 4.08 over the past decade. While the company's 10-year median is 2.84 vs. the industry median of 1.62, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Debt-to-EBITDA of 2.82 is 74.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Egyptian International Pharmaceutical Investments. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Debt-to-EBITDA is 2.82, which is near median its own 10-year median of 2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£60.27, compared to a current price of E£127.30 — trading 111.2% above its estimated fair value. The current Debt-to-EBITDA is 2.82, which is near median its 10-year median of 2.84 and 74.1% above the Drug Manufacturers industry median of 1.62. Egyptian International Pharmaceutical Investments' overall GF Score™ is 67/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Debt-to-EBITDA is 2.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£127.30 is trading 111.2% above its estimated GF Value™ of E£60.27.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Debt-to-EBITDA: 2.82 (near median its 10-year median of 2.84)
GF Value™: E£60.27 vs. price of E£127.30 (111.2% above fair value)
Industry Position: 74.1% above the Drug Manufacturers median (#519 of 675)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
67GF Score
Get the complete analysis for CAI:PHAR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
